Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680586 · ClinicalTrials.gov registry record · Early Phase 1
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma
A Early Phase 1 study of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03680586: Active Early Phase 1 study of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, sponsored by M.D. Anderson Cancer Center.
NCT03680586 is a Early Phase 1 study of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03680586, a Early Phase 1 study of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphoma. Ultra low-dose radiation therapy may be able to kill tumor cells and shrink tumors while having fewer side effects in patients with MALT lymphoma.
Primary Outcome
The complete response rate at one year will be estimated along with 95% confidence intervals.
Conditions Studied
Interventions
- DRUG Radiation Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2028-04-30 |
| Phase | Early Phase 1 |
What the registry record for NCT03680586 still lists
NCT03680586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT03680586 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03680586 about?
NCT03680586 is a clinical study titled "Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma". This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphoma. Ultra low-dose radiation therapy may be able to kill tumor cells and shrink tumors while having fewer side effects in patients with MALT ...
What is the current status of trial NCT03680586?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2019-02-04. Estimated completion is 2028-04-30.
What conditions does trial NCT03680586 study?
This clinical trial studies the following conditions: Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
What interventions are being tested in trial NCT03680586?
The interventions under investigation include: Radiation Therapy (DRUG).
Who is sponsoring clinical trial NCT03680586?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680586 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03680586's enrollment target sits among peer trials
25 1000th of 2000 higher than 965 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI